$REGN earnings report

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025; GAAP EPS increased 35% to $18.45 and non-GAAP EPS increased 70% to $20.07. AlphAI read Regeneron Pharmaceuticals's Q3 FY2026 filing as strong. 3 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readREGN · Q3 2026 · ended September 30, 2026

Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025; GAAP EPS increased 35% to $18.45 and non-GAAP EPS increased 70% to $20.07.

✓Strong quarter

Total revenues grew 36%, led by a 68% increase in Sanofi collaboration revenue, while GAAP diluted EPS rose 35% and non-GAAP diluted EPS rose 70%. EYLEA HD U.S. sales, global Libtayo sales, and Dupixent global sales all grew, although EYLEA U.S. sales declined 41%.

Revenue
$5.12B
36 % y/y
EYLEA HD - U.S.
$699M
62 % y/y
Gross margin · GAAP
82%
EPS · non-GAAP
$ 20.07
70 % y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 total revenuesGAAP$5.12B–36 %
Q3 2026 net product salesGAAP$1.81B–14 %
Q3 2026 collaboration revenueGAAP$3.00B––
Q3 2026 other revenueGAAP$310M–57 %
Q3 2026 income from operationsGAAP$2.05B––
Q3 2026 net incomeGAAP$1.95B–33 %
Q3 2026 net income per share - basicGAAP$ 19.16––
Q3 2026 net income per share - dilutedGAAP$ 18.45–35 %
Q3 2026 non-GAAP net incomenon-GAAP$2.15B–67 %
Q3 2026 non-GAAP net income per share - basicnon-GAAP$ 21.14––
Q3 2026 non-GAAP net income per share - dilutednon-GAAP$ 20.07–70 %
Q3 2026 research and developmentGAAP$1.79B–22 %
Q3 2026 research and developmentnon-GAAP$1.65B–23 %
Q3 2026 acquired in-process research and developmentGAAP$21.5M–(73 %)
Q3 2026 selling, general, and administrativeGAAP$677.8M–3 %
Q3 2026 selling, general, and administrativenon-GAAP$588.3M–9 %
Q3 2026 cost of goods soldGAAP$321.7M–15 %
Q3 2026 cost of goods soldnon-GAAP$245.7M–8 %
Q3 2026 gross margin on net product salesGAAP82%––
Q3 2026 gross margin on net product salesnon-GAAP86%––
Q3 2026 cost of collaboration and contract manufacturingGAAP$251.9M–5 %
Q3 2026 effective tax rateGAAP14.7%––
Q3 2026 effective tax ratenon-GAAP15.0%––
Nine months ended September 30, 2026 total revenuesGAAP$13.01B––
Nine months ended September 30, 2026 net incomeGAAP$3.97B––
Nine months ended September 30, 2026 net income per share - dilutedGAAP$ 37.37––
Nine months ended September 30, 2026 non-GAAP net incomenon-GAAP$4.73B––
Nine months ended September 30, 2026 non-GAAP net income per share - dilutednon-GAAP$ 43.70––
Nine months ended September 30, 2026 gross margin on net product salesGAAP79%––
Nine months ended September 30, 2026 gross margin on net product salesnon-GAAP86%––
Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP$3.68B––
Nine months ended September 30, 2026 capital expendituresother$771M––
Nine months ended September 30, 2026 free cash flownon-GAAP$2.90B––

Segments

SegmentRevenueq/qy/y
EYLEA HD - U.S.Higher sales volumes driven by increased demand, partly offset by a lower net selling price.$699M–62 %
EYLEA - U.S.Lower sales volumes resulting from continued competitive pressures and the continued transition of patients to EYLEA HD.$400M–(41 %)
Total EYLEA HD and EYLEA - U.S.EYLEA HD growth was offset by lower EYLEA sales.$1.10B–(1 %)
Libtayo - U.S.Higher sales volumes driven by increased demand.$396M–81 %
Libtayo - ROWNo driver quantified in the release.$154M–5 %
Total Libtayo - GlobalU.S. net product sales increased primarily due to higher sales volumes driven by increased demand.$550M–51 %
Praluent - U.S.No driver quantified in the release.$ 81–21 %
Evkeeza - U.S.No driver quantified in the release.$ 55–28 %
Lynozyfic - GlobalPercentage was not meaningful or greater than 100%.$ 19––
Other products - GlobalPercentage was not meaningful or greater than 100%.$ 1––
Sanofi collaboration revenueHigher share of profits from commercialization of antibodies, primarily associated with higher Dupixent sales, and the Sanofi Development Balance no longer reduced collaboration revenue.$2.72B–68 %
Bayer collaboration revenueNo driver quantified in the release.$267M–(23 %)
Other collaboration revenueNo driver quantified in the release.$ 10–67 %
Dupixent global net sales, recorded by SanofiHigher Dupixent sales contributed to higher Sanofi collaboration revenue.$6.54B–35 %
EYLEA HD global net salesU.S. demand-driven volume growth was partly offset by a lower net selling price.$1.08B–63 %
EYLEA global net salesContinued competitive pressures and the transition of patients to EYLEA HD.$658.4M–(49 %)
Kevzara global net sales, recorded by SanofiNo driver quantified in the release.$255.6M–66 %

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Gross marginGAAP gross margin on net product sales: 78%–79%; non-GAAP gross margin on net product sales: 84%–85%
  • Operating expensesGAAP R&D: $6.500–$6.635 billion; non-GAAP R&D: $5.950–$6.050 billion; GAAP SG&A: $2.830–$2.960 billion; non-GAAP SG&A: $2.500–$2.600 billion; GAAP COCM: $985 million–$1.035 billion; non-GAAP COCM: $970 million–$1.020 billion
  • Tax rateGAAP effective tax rate: 13%–14%; non-GAAP effective tax rate: 14%–15%
  • NoteCapital expenditures: $1.030–$1.100 billion
  • NoteThe Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release.

Capital returns

  • During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock.
  • As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company's share repurchase programs.
  • In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.

What drove it

  • Sanofi collaboration revenue rose as the Company's share of profits from commercialization of antibodies increased to $2.575 billion from $1.456 billion, primarily associated with higher Dupixent sales.
  • The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.
  • GAAP and non-GAAP R&D increased due to clinical pipeline advancement and increased manufacturing activity associated with product candidates.
  • The Company received an up-front payment of $1.0 billion under its expanded Sanofi antibody collaboration, to be recognized as collaboration revenue in the fourth quarter of 2026.
  • Pasatru was approved by the FDA in August 2026 for adults with FOP.

Concerns

  • EYLEA U.S. net product sales decreased due to continued competitive pressures and continued patient transition to EYLEA HD.
  • Bayer collaboration revenue decreased 23%.
  • GAAP gross margin on net product sales for the nine months ended September 30, 2026 was 79%, compared to 82% in the prior-year period; the reconciliation identified temporary manufacturing interruption-related costs of 3%.
  • GAAP other income (expense), net decreased primarily due to lower net gains on marketable and other securities.

What to watch

  • FDA target action date for cemdisiran in generalized myasthenia gravis is expected next month.
  • The FDA target action date for Ordspono in relapsed or refractory diffuse large B-cell lymphoma is February 2027.
  • The FDA target action date for the Libtayo alternative dosing schedule sBLA is March 2027.
  • The Company plans to initiate a Phase 3 study in MASH/MASLD in the fourth quarter of 2026.
  • The Company plans to report Phase 2 baloncibart results in POTS in November 2026 and plans to initiate a Phase 3 study in the first half of 2027, pending regulatory feedback.
  • The $1.0 billion Sanofi up-front payment is expected to be recognized as collaboration revenue in the fourth quarter of 2026.

Balance sheet and cash flow

  • Cash and marketable securities as of September 30, 2026: $ 18,858.5; December 31, 2025: $ 18,865.8.
  • Long-term debt as of September 30, 2026: $ 1,987.0; December 31, 2025: $ 1,985.9.
  • Accounts receivable, net as of September 30, 2026: $ 7,578.6; December 31, 2025: $ 5,741.1.
  • Inventories as of September 30, 2026: $ 2,894.6; December 31, 2025: $ 3,200.8.
  • Nine months ended September 30, 2026 net cash provided by operating activities: $ 3,675.3; capital expenditures: $ 771.0; free cash flow: $ 2,904.3.

Analysis

Regeneron reported a strong third quarter, with total revenues of $ 5,115.8 versus $ 3,754.3 in the third quarter of 2025. Collaboration revenue of $ 3,000.5 was the largest revenue stream and included $ 2,724.0 from Sanofi. Sanofi collaboration revenue benefited from higher profit sharing on antibody commercialization, primarily linked to higher Dupixent sales, and from the end of Sanofi Development Balance reductions beginning in the third quarter. Net product sales increased to $ 1,805.3 from $ 1,587.7.

Commercial performance reflected continued portfolio mix changes. EYLEA HD U.S. sales rose 62% to $ 699, supported by demand-driven volume gains, while EYLEA U.S. sales fell 41% to $ 400 amid competitive pressures and patient transitions to EYLEA HD. Combined U.S. EYLEA HD and EYLEA sales were $ 1,099, down 1%. Libtayo global sales increased 51% to $ 550, including 81% growth in U.S. sales to $ 396. Dupixent global net sales recorded by Sanofi increased 35% to $ 6,540.5.

Profitability expanded despite higher development spending. GAAP net income was $ 1,948.7 and non-GAAP net income was $ 2,150.0. GAAP diluted EPS was $ 18.45, while non-GAAP diluted EPS was $ 20.07. GAAP R&D increased to $ 1,794.7 and non-GAAP R&D increased to $ 1,653.8, with the release citing pipeline advancement and increased manufacturing activity. Third-quarter GAAP and non-GAAP gross margin on net product sales were unchanged at 82% and 86%, respectively.

Capital deployment included $2.3 billion of common-stock repurchases during the nine months ended September 30, 2026, with $2.2 billion remaining authorized at period end. The company declared a $0.94 per-share cash dividend in October. Cash and marketable securities were $ 18,858.5 and long-term debt was $ 1,987.0 as of September 30, 2026. Nine-month free cash flow was $ 2,904.3.

Full-year 2026 guidance calls for GAAP R&D of $6.500–$6.635 billion, non-GAAP R&D of $5.950–$6.050 billion, GAAP gross margin on net product sales of 78%–79%, and non-GAAP gross margin of 84%–85%. The company also expects capital expenditures of $1.030–$1.100 billion. The expanded Sanofi agreement produced a $1.0 billion up-front payment expected to be recognized as collaboration revenue in the fourth quarter of 2026, with potential additional milestones of up to $7.0 billion.

Management, verbatim

This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales.

Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron

Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever.

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported Q3 operating metrics were not provided.
  • Quarterly operating cash flow and quarterly free cash flow were not provided.
  • A full-year 2026 revenue guidance figure was not provided.
  • Quarterly dividend cash amount and dividend payment history were not provided.
  • Total debt beyond the reported long-term debt line was not provided.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

third quarter 2026

AlphAI · Earnings readREGN · third quarter 2026 · ended September 30, 2026

Regeneron expects an acquired IPR&D charge in the third quarter 2026 and expands its Sanofi antibody collaboration through four new long-acting antibodies.

→Mixed quarter

The filing provides no finalized operating results, revenue, profitability, or cash-flow data. It discloses an expected acquired IPR&D charge affecting third-quarter GAAP and non-GAAP EPS alongside a collaboration amendment that includes an upfront payment and potential milestone payments.

EPS · non-GAAP
approximately $0.18

Key metrics

as reported
MetricValueq/qy/y
Acquired in-process research and development (IPR&D) charge, third quarter 2026, pre-taxotherapproximately $22 million––
Expected impact on GAAP net income per diluted share, third quarter 2026GAAPapproximately $0.18––
Expected impact on non-GAAP net income per diluted share, third quarter 2026non-GAAPapproximately $0.18––

What drove it

  • Sanofi will make an upfront payment to Regeneron of $1.0 billion pursuant to the Sixth Amendment.
  • Regeneron will be entitled to receive up to an additional $7.0 billion of payments in the aggregate upon achievement of certain development, regulatory, and commercial milestones with respect to the New Licensed Products.
  • Regeneron and Sanofi agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and IL-4xIL-13.
  • Global profits realized on sales of New Licensed Products will be shared equally between Regeneron and Sanofi.
  • Development costs for licensed products under the Antibody LCA, including the New Licensed Products, will be shared equally by the parties.

Concerns

  • Third-quarter 2026 results have not been finalized and remain subject to financial statement closing procedures.
  • The expected acquired IPR&D charge is expected to negatively affect both GAAP and non-GAAP net income per diluted share.
  • Development costs in excess of a budget cap for all New Licensed Products will be Regeneron's responsibility, subject to certain rights to recoup excess costs in future years.
  • The filing does not report revenue, product sales, margins, operating income, net income, cash flow, cash, debt, or finalized EPS.

What to watch

  • Final third-quarter 2026 financial results and whether they differ from the preliminary unaudited estimates.
  • Recognition and financial presentation of the Sanofi upfront payment.
  • Progress of the initial global development plan for the IL-13 asset and development plans for the other New Licensed Products.
  • Whether Regeneron exercises its option to include lunsekimig or another Sanofi early development product in the collaboration.
  • Development spending relative to the budget cap for the New Licensed Products.

Analysis

This is not a full earnings release. Regeneron states that its third-quarter 2026 results have not been finalized and provides only a preliminary expected acquired IPR&D charge. The Company expects an acquired IPR&D charge of approximately $22 million on a pre-tax basis, with an expected negative impact of approximately $0.18 on each of GAAP and non-GAAP net income per diluted share. No revenue, product-sales, margin, operating-income, net-income, or cash-flow results are reported.

The principal disclosure is the Sixth Amendment to the Antibody LCA with Sanofi. The parties will co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies, while global profits from their sales will be shared equally. Sanofi will make an upfront payment to Regeneron of $1.0 billion, and Regeneron may receive up to an additional $7.0 billion upon specified development, regulatory, and commercial milestones.

The agreement extends Regeneron's development and U.S. regulatory role for the New Licensed Products, while Sanofi will lead commercialization and regulatory activities outside the United States. Development costs will be shared equally, but Regeneron will bear development costs above the budget cap for all New Licensed Products, subject to specified future recoupment rights. This allocation makes the scale and timing of development spending an important item for the finalized financial results and subsequent reporting.

The filing also gives Regeneron an asset-by-asset option, after certain ongoing clinical trials, to include Sanofi's Phase 2/3 asset lunsekimig and another Sanofi early development product. Exercising that option would require Regeneron to reimburse Sanofi for certain related development costs. Investors will need the final third-quarter release to assess the preliminary IPR&D charge in the context of operating performance and to obtain any accounting detail related to the collaboration payments.

Not in the filing

stated, not guessed
  • Total revenue and prior-period comparisons
  • Product revenue and segment revenue
  • Gross margin
  • Operating expenses
  • Operating income
  • GAAP net income
  • Non-GAAP net income
  • GAAP EPS excluding the stated expected IPR&D impact
  • Non-GAAP EPS excluding the stated expected IPR&D impact
  • Operating cash flow
  • Free cash flow
  • Cash and cash equivalents
  • Debt
  • Share repurchases
  • Dividends
  • Forward revenue guidance
  • Forward gross-margin guidance
  • Forward operating-expense guidance
  • Forward tax-rate guidance
  • Named executive quotes
  • The previous outlook covered the full year 2026 only, and this release reports the third quarter, so there is nothing comparable.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readREGN · Q2 2026 · ended June 30, 2026

Second quarter 2026 revenue rose 17% to $4,291 million, supported by Sanofi collaboration revenue and growth in EYLEA HD and Libtayo, while GAAP net income declined 7% to $1,297 million.

✓Solid quarter

Revenue and non-GAAP diluted EPS increased by double digits, driven by higher Sanofi collaboration revenue and strong EYLEA HD and Libtayo sales. GAAP net income declined, gross margin contracted, and full-year gross-margin guidance was lowered.

Revenue
$4.29B
17% y/y
EYLEA HD - U.S.
$596M
52% y/y
Gross margin · GAAP
78%
EPS · non-GAAP
$14.29
11% y/y

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$4.29B–17%
Total net product salesGAAP$1.64B–1%
Sanofi collaboration revenueGAAP$2.17B–51%
Bayer collaboration revenueGAAP$276M–(33%)
Other collaboration revenueGAAP$6M––
Other revenueGAAP$193M–5%
Company's share of profits from the commercialization of antibodiesother$2.03B––
GAAP net incomeGAAP$1.30B–(7%)
GAAP net income per share - dilutedGAAP$12.23–(5%)
Non-GAAP net incomenon-GAAP$1.54B–8%
Non-GAAP net income per share - dilutednon-GAAP$14.29–11%
Research and development (R&D)GAAP$1.63B–15%
Research and development (R&D)non-GAAP$1.5B–17%
Acquired in-process research and development (IPR&D)GAAP$127M––
Selling, general, and administrative (SG&A)GAAP$662M–4%
Selling, general, and administrative (SG&A)non-GAAP$574M–6%
Cost of goods sold (COGS)GAAP$361M–31%
Cost of goods sold (COGS)non-GAAP$221M–— %
Gross margin on net product salesGAAP78%––
Gross margin on net product salesnon-GAAP87%––
Cost of collaboration and contract manufacturing (COCM)GAAP$216M–(15%)
GAAP effective tax rate (ETR)GAAP15.1%––
Non-GAAP effective tax rate (ETR)non-GAAP15.5%––

Segments

SegmentRevenueq/qy/y
EYLEA HD - U.S.Higher sales volumes driven by increased demand, partly offset by a lower net selling price.$596M–52%
EYLEA - U.S.Lower sales volumes driven by decreased demand, continued competitive pressures, continued transition of patients to EYLEA HD, and a lower net selling price.$412M–(45%)
Total EYLEA HD and EYLEA - U.S.EYLEA HD growth was more than offset by lower EYLEA sales.$1.01B–(12%)
Libtayo - U.S.Global Libtayo sales increased primarily due to higher sales volumes driven by increased demand.$343M–38%
Libtayo - ROWGlobal Libtayo sales increased primarily due to higher sales volumes driven by increased demand.$146M–13%
Total Libtayo - GlobalHigher sales volumes driven by increased demand.$489M–30%
Praluent - U.S.Not discussed.$75M–14%
Evkeeza - U.S.Not discussed.$53M–29%
Lynozyfic - GlobalNot discussed.$17M––
SanofiHigher share of profits from commercialization of antibodies, primarily associated with an increase in Dupixent sales.$2.17B–51%
BayerNot discussed.$276M–(33%)
Other revenueNot discussed.$193M–5%

Full year 2026 outlook

  • Gross marginGAAP gross margin on net product sales: 78%–79%; Non-GAAP gross margin on net product sales: 84%–85%
  • Operating expensesGAAP R&D: $6.500–$6.635 billion; Non-GAAP R&D: $5.950–$6.050 billion; GAAP SG&A: $2.830–$2.960 billion; Non-GAAP SG&A: $2.500–$2.600 billion
  • NoteGAAP COCM: $985 million–$1.035 billion

Capital returns

  • During the three months ended June 30, 2026, the Company repurchased $1.2 billion of its common stock.
  • During the six months ended June 30, 2026, the Company repurchased $2.0 billion of its common stock.
  • As of June 30, 2026, $2.5 billion remained available for share repurchases under the Company's share repurchase programs.
  • In July 2026, the board declared a cash dividend of $0.94 per share, payable on August 31, 2026 to shareholders of record as of August 18, 2026.
  • The Company said nearly $3.0 billion was deployed in the first half of the year to share repurchases, dividends, capital expenditures, and business development.

What drove it

  • Total revenue growth reflected a 51% increase in Sanofi collaboration revenue, primarily associated with increased Dupixent sales.
  • U.S. EYLEA HD sales grew 52% through higher sales volumes driven by increased demand, partly offset by a lower net selling price.
  • Global Libtayo sales grew 30%, primarily due to higher sales volumes driven by increased demand.
  • R&D expense growth was driven by the Company's mid- and late-stage clinical pipeline.
  • The Company reported approximately 50 product candidates in clinical development.

Concerns

  • U.S. EYLEA sales declined 45% amid lower demand, competitive pressures, patient transitions to EYLEA HD, and a lower net selling price.
  • GAAP gross margin on net product sales fell to 78% from 83% due primarily to unabsorbed manufacturing costs following the temporary interruption of bulk manufacturing production at Limerick, Ireland.
  • GAAP net income declined 7% and GAAP diluted EPS declined 5%, while acquired IPR&D expense was $127 million.
  • The Phase 3 fianlimab plus cemiplimab melanoma trial did not reach statistical significance for its primary progression-free-survival endpoint compared to pembrolizumab monotherapy.
  • GAAP and non-GAAP effective tax rates increased to 15.1% and 15.5%, respectively.

What to watch

  • The step-up in collaboration profits beginning in the third quarter of 2026 following repayment of the Sanofi Development Balance.
  • Whether bulk manufacturing production at the Limerick, Ireland facility remains at normal levels following its return to normal levels as of the end of the second quarter of 2026.
  • The FDA target action date in November 2026 for cemdisiran in adult patients with generalized myasthenia gravis.
  • Execution of the Phase 2 registrational-intent portion of the LINKER-AL2 trial for Lynozyfic in systemic amyloid light chain amyloidosis.
  • Progress of the Phase 3 peripheral artery disease study for cenvacibart and amrecibart.

Balance sheet and cash flow

  • The Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026.
  • The Sanofi Development Balance will no longer reduce Sanofi collaboration revenue beginning in the third quarter of 2026.

Analysis

Regeneron reported second-quarter 2026 total revenues of $4,291 million, up 17% from $3,676 million. The primary contributor was Sanofi collaboration revenue, which increased 51% to $2,174 million. The Company attributed this to a higher share of commercialization profits from antibodies, primarily associated with higher Dupixent sales. Dupixent global net sales, recorded by Sanofi, increased 38% to $6.0 billion.

Product sales were broadly flat, with total net product sales of $1,642 million versus $1,631 million. U.S. EYLEA HD sales increased 52% to $596 million on demand-led volume growth, but U.S. EYLEA sales declined 45% to $412 million amid competitive pressure, lower demand, patient migration to EYLEA HD, and lower net selling prices. Combined U.S. EYLEA HD and EYLEA sales declined 12% to $1,008 million. Libtayo was a key positive, with global sales up 30% to $489 million, primarily due to higher demand-driven sales volumes.

Profitability was mixed. Non-GAAP net income increased 8% to $1,543 million and non-GAAP diluted EPS increased 11% to $14.29. GAAP net income declined 7% to $1,297 million and GAAP diluted EPS fell 5% to $12.23. The period included $127 million of acquired IPR&D expense, while GAAP gross margin on net product sales declined to 78% from 83% because of unabsorbed manufacturing costs related to the temporary bulk-manufacturing interruption in Limerick, Ireland. The Company said production returned to normal levels by quarter end and product availability was not affected.

The Company fully repaid the Sanofi Development Balance as of the end of the second quarter. Regeneron said the obligation will no longer reduce Sanofi collaboration revenue beginning in the third quarter, making the collaboration-profit trajectory a central near-term item. Capital returns included $1.2 billion in common-stock repurchases during the quarter, with $2.5 billion remaining under repurchase programs as of June 30, 2026, alongside a declared $0.94 per-share cash dividend.

Full-year guidance shown in the filing indicates lower gross-margin ranges than the prior ranges displayed in the guidance table, with GAAP gross margin on net product sales at 78%–79% and non-GAAP gross margin at 84%–85%. The filing also shows updated ranges for R&D, SG&A, and GAAP COCM. Pipeline attention centers on the November 2026 FDA target action date for cemdisiran in generalized myasthenia gravis, while the fianlimab melanoma trial outcome was a setback because it did not achieve its primary endpoint.

Management, verbatim

Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline.

Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer

Second quarter revenues grew 17% and non-GAAP net income per share grew 11%, marking our second consecutive quarter of double-digit growth on both measures.

Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported revenue, product sales, collaboration revenue, earnings, EPS, operating expenses, gross margin, and tax rates were not reported.
  • GAAP and non-GAAP operating income were not reported in the provided filing text.
  • Operating cash flow, free cash flow, cash balance, marketable securities balance, total debt, and net debt were not reported in the provided filing text.
  • Full-year 2026 revenue guidance and tax-rate guidance were not reported in the provided filing text.
  • The provided filing text is truncated in the 2026 guidance table, so the updated non-GAAP COCM range and any following guidance items are not available.
  • A previous earnings release outlook section was not provided, so actual results cannot be assessed against prior guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about REGN earnings dates

When is Regeneron Pharmaceuticals's next earnings date?
AlphAI has no date for REGN yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.